European Psychiatry (Apr 2021)
Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis
Abstract
Introduction Long-acting injectable antipsychotics (LAIs) can reduce relapse and hospitalization risk but they are not widely used in first psychotic episode (FEP) patientes. Objectives To examine the effcacy of two of the most used second generation LAI antipsychotics (paliperione 3 monthly and aripiprazol 1 monthly) to reduce hospitalization rates. Methods We evaluated in a naturalistic study a sample of patients (n=277) with a FEP. We carried out a mirror-design study to compare the number of hospitalizations and days in hospital before and after the introduction of LAI paliperidone (3 monthly) or LAI aripiprazol. In our Early Intervention Services (Lehenak) antipsychotic treatment is not protocolized and is established for each patient according to the psychiatrist criteria. Results We review the oucome of 277 FEP treated in our Early Intervention Service “Lehenak” with LAI paliperidone 3 monthly (n=156) or LAI Aripiprazol (n=121) Pre LAI Mirror Period Post LAI Mirror Period Within group comparisons (paired t-test) t p Aripiprazol LAI number of Hospitalizations (mean, standard deviation) 2.31 (1.72) 0.73 (1.23) 17.4 (<0.001) Paliperidone LAI 3 monthly number of Hospitalizations number 0,68 (0.93) 0.15 (0.47) 4.62 (<0.001) Aripiprazol LAI Days in Hospital 30.26 (33.52) 17.02 (38.19) 2.93 (0.004) Paliperidone LAI 3 monthly Days in hospital 12.63 (24.23) 3.40 (14.18)) 7.5 (<0.001) Conclusions Both LAI paliperidone 3 monthly and LAI aripiprazol had a postive impact on hospitalIzation rate, decreasing them significantly after their introduction. These data also support a more extensive use of LAI paliperidone 3 monthly in FEP. Disclosure Presenting author has received honouraria for lectures or advisory boards from Janssen, Otsuka, Lundbeck and Angelini in the last five years
Keywords
